Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.
暂无分享，去创建一个
S. Hilsenbeck | R. Schiff | Jenny C. Chang | M. Goetz | C. Osborne | R. Nanda | A. Pavlick | Tao Wang | A. Forero | I. Mayer | Angel A. Rodriguez | C. Gutierrez | M. Rimawi | C. K. Osborne | Anne C Pavlick | A. Pavlick